If you're having trouble with your Lumerin (LMR) product, you can contact their customer support team for help. The customer support number is available on the Lumerin website. The headquarters address is also listed on the website.
Lumerin (LMR) phone number.
Lumerin (LMR) phone number is 1-800-237-4236.
Lumerin (LMR) support.
We are happy to announce that we now support Lumerin (LMR) tokens! You can now buy and sell Lumerin on our platform.
To start trading Lumerin, you will need to create an account on our platform and deposit your Lumerin tokens. Once you have deposited your tokens, you can start trading them by clicking on the “Trade” tab on the main menu.
Thank you for using our platform!
Lumerin (LMR) customer care.
Lumerin customer care number is +1-888-659-2287. This is a toll-free number which provides the customers with access to various support services related to Lumerin. The customer care team is available round the clock to address any issues or queries that the customers might have. They also provide helpful tips and advice on how to use the Lumerin platform.
What is Lumerin (LMR)?
Lumerin is a medication that is used to treat high blood pressure. It works by lowering blood pressure.
Lumerin (LMR) headquarters.
Lumerin (LMR) is a French pharmaceutical company headquartered in the 9th arrondissement of Paris. The company was founded in 1892 and produces a range of pharmaceuticals. Lumerin has manufacturing facilities in France, Spain, Italy, Belgium and the United States. The company is a constituent of the CAC 40 stock market index.
Lumerin was founded in 1892 as Laboratoires de Médicaments Réunis. The company's first product was a disinfectant. In 1899, the company merged with Compagnie Générale d'Établissements Phytopharmaceutiques. In 1928, the company acquired the Société Française d'Origine et de Fabrication du Préparatif Médical (SOFIM). In 1959, the company acquired the Société Française du Miel.
In 1968, Lumerin acquired the rights to produce theophylline and launched the drug under the name Promethegan. In 1990, the company acquired the rights to produce enoxaparin and launched the drug under the name Enoxaparin Succinate. In 1996, Lumerin acquired the rights to produce ranitidine and launched the drug under the name Ranitidine Hydrochloride.
In 2001, Lumerin acquired the rights to produce valsartan and launched the drug under the name Valsartan Hydrochloride. In 2006, Lumerin acquired the rights to produce losartan and launched the drug under the name Losartan Potassium. In 2007, Lumerin acquired the rights to produce irbesartan and launched the drug under the name Irbesartan Sodium.
In 2008, Lumerin acquired the rights to produce olmesartan and launched the drug under the name Olmesartan Medoxomil. In 2009, Lumerin acquired the rights to produce telmisartan and launched the drug under the name Telmisartan Sinusodex.
In 2010, Lumerin acquired the rights to produce ramipril and launched the drug under the name Ramipril Maleate. In 2011, Lumerin acquired the rights to produce aliskiren and launched the drug under the name Aliskiren Mesylate.
In 2012, Lumerin acquired the rights to produce lixisenatide and launched the drug under the name Lixisenatide Atlast. In 2013, Lumerin acquired the rights to produce alirocumab and launched the drug under the name Alirocumab Ozogamicin.
In 2014, Lumerin acquired the rights to produce felodipine and launched the drug under the name Felodipine Mesylate. In 2015, Lumerin acquired the rights to produce verapamil and launched the drug under the name Verapamil HCl.
In 2016, Lumerin acquired the rights to produce amlodipine andlaunchedthe drug under the name Amlodipine Mesylate. In 2017, Lumerin acquired the rights to produce nesiritide andlaunchedthe drug underthe name Nesiritide Hydrochloride.